Shanghai GenoFusion Biotech and Illumina Sign Letter of Intent for Continued Deep Collaboration at the 4th China International Import Expo

Shanghai, November 202111/PR Newswire/ --2021On November 7, SEQUANTA was invited to participate in the 4th China International Import Expo and signed a letter of intent for ongoing in-depth cooperation with Illumina, the global leader in gene sequencing and chip technology.

Both Parties Sign Intention Letter for Continuous In-Depth Cooperation

According to the cooperation agreement, SEQUANTA will leverage its high-level technology R&D capabilities in line with international standards and rely on Illumina's globally leading high-throughput sequencing technology to meet extensive and complex market demands, enhance the commercial layout in China’s scientific research field, and jointly promote the comprehensive development of high-throughput sequencing technology in multi-omics businesses.

Li Qing, Vice President of Illumina Worldwide and General Manager of Greater China, believes that localization is crucial for Illumina's development in China. Due to the unique nature of the gene sequencing industry, the core of the China strategy lies in empowering collaborations and building an ecosystem through respective open platforms. In the future, Illumina will partner with SEQUANTA to jointly create a localized genetic testing industry ecosystem.

SEQUANTA Founder and CEO Sun Lele stated that, through its extensive clinical and research sample service experience in multi-omics fields such as genomics, transcriptomics, proteomics, and epigenomics, SEQUANTA leverages the first-mover advantage of high-throughput multi-omics sequencing and high-performance big data analysis technology. This not only allows SEQUANTA to cover current mainstream international technology platforms but also places it at the forefront of data analysis in China. SEQUANTA has rapidly advanced the development of commercial applications, fully supporting scientific research related to cancer, immunity, neuroscience, infectious diseases, cardiovascular health, metabolism, reproduction, and other areas concerning global human health.

SEQUANTA Founder and CEO Sun Lele

At this signing ceremony, SEQUANTA and Illumina reached a comprehensive consensus and signed a letter of intent to continue their in-depth cooperation. Both parties hope to further deepen strategic leadership based on the foundation of previous successful collaborations, strengthen the strategic basis, leverage their respective strengths, and move forward together. They aim to continuously provide one-stop precision medicine solutions for pharmaceutical companies, clinical settings, and research institutions in the research and development and application of scientific testing technologies, jointly contributing to the development of China's healthcare industry.